FI3694526T3 - Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten - Google Patents

Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten Download PDF

Info

Publication number
FI3694526T3
FI3694526T3 FIEP18865483.4T FI18865483T FI3694526T3 FI 3694526 T3 FI3694526 T3 FI 3694526T3 FI 18865483 T FI18865483 T FI 18865483T FI 3694526 T3 FI3694526 T3 FI 3694526T3
Authority
FI
Finland
Prior art keywords
cystic fibrosis
patient
agnostic
genotype
rescue
Prior art date
Application number
FIEP18865483.4T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Martin D Burke
Katrina A Muraglia
Rajeev S Chorghade
Michael J Welsh
Original Assignee
Univ Illinois
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Univ Iowa Res Found filed Critical Univ Illinois
Application granted granted Critical
Publication of FI3694526T3 publication Critical patent/FI3694526T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP18865483.4T 2017-10-11 2018-10-11 Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten FI3694526T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762570795P 2017-10-11 2017-10-11
PCT/US2018/055435 WO2019075214A2 (en) 2017-10-11 2018-10-11 INDEPENDENT RESCUEING OF THE GENOTYPE OF CYSTIC FIBROSIS WITH BICARBONATE CHANNELS WITH SMALL MOLECULES

Publications (1)

Publication Number Publication Date
FI3694526T3 true FI3694526T3 (fi) 2025-02-06

Family

ID=66100102

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18865483.4T FI3694526T3 (fi) 2017-10-11 2018-10-11 Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten

Country Status (10)

Country Link
US (3) US12090164B2 (enExample)
EP (1) EP3694526B1 (enExample)
JP (2) JP7355335B2 (enExample)
AU (2) AU2018348214C1 (enExample)
CA (1) CA3076246A1 (enExample)
DK (1) DK3694526T3 (enExample)
ES (1) ES3009563T3 (enExample)
FI (1) FI3694526T3 (enExample)
PT (1) PT3694526T (enExample)
WO (1) WO2019075214A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7355335B2 (ja) 2017-10-11 2023-10-03 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 小分子重炭酸イオンチャネルを用いた嚢胞性線維症の遺伝子型非依存性救済
KR20240164801A (ko) 2022-03-21 2024-11-20 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 암포테리신 b의 지질-코팅된 결정을 포함하는 이온 채널 보형 조성물
WO2025019806A2 (en) * 2023-07-19 2025-01-23 The Board Of Trustees Of The University Of Illinois Restoring physiology with small molecule mimics of missing proteins
WO2025064626A1 (en) * 2023-09-20 2025-03-27 The Board Of Trustees Of The University Of Illinois Additive effects for molecular prosthetcs and cftr modulators in cf epithelia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
JP5118302B2 (ja) * 2002-10-29 2013-01-16 トランセイブ, インク. 抗感染剤の徐放
TWI249408B (en) 2003-12-10 2006-02-21 Ind Tech Res Inst New antifungal formulation and manufacturing method thereof
ATE476965T1 (de) * 2004-06-11 2010-08-15 Verma Jitendra Nath Sterol-angereicherte multilamellare amphotericin- enthaltende liposomen in kochsalzlösung und herstellungsverfahren
WO2011050311A1 (en) 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US20180015115A1 (en) * 2014-11-04 2018-01-18 The Board Of Trustees Of The University Of Illinois Restoring physiology with small molecule mimics of missing proteins
DK3439668T3 (da) * 2016-04-08 2024-09-02 Univ Illinois Småmolekylemedieret genoprettelse af luftvejsoverfladefysiologi i lungeepiteler ved human cystisk fibrose
WO2017181193A2 (en) * 2016-04-15 2017-10-19 The Uab Research Foundation Methods and compounds for stimulating read-through of premature termination codons
JP7355335B2 (ja) 2017-10-11 2023-10-03 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 小分子重炭酸イオンチャネルを用いた嚢胞性線維症の遺伝子型非依存性救済

Also Published As

Publication number Publication date
WO2019075214A2 (en) 2019-04-18
JP2020536859A (ja) 2020-12-17
PT3694526T (pt) 2025-01-20
US20200352970A1 (en) 2020-11-12
DK3694526T3 (da) 2025-02-03
CA3076246A1 (en) 2019-04-18
EP3694526A2 (en) 2020-08-19
WO2019075214A3 (en) 2020-04-02
ES3009563T3 (en) 2025-03-27
AU2018348214B2 (en) 2024-08-08
US20250009775A1 (en) 2025-01-09
JP7355335B2 (ja) 2023-10-03
AU2024259758A1 (en) 2024-11-21
JP2023126932A (ja) 2023-09-12
AU2018348214A1 (en) 2020-04-23
US20250000886A1 (en) 2025-01-02
EP3694526B1 (en) 2024-12-04
EP3694526A4 (en) 2021-06-09
US12090164B2 (en) 2024-09-17
AU2018348214C1 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
FI3694526T3 (fi) Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
PH12018500765A1 (en) N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
PH12018500088A1 (en) Substituted tricyclics and method of use
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
WO2017091767A3 (en) Drug formulations for cancer treatment
MY161078A (en) Topical formulation for a jak inhibitor
EP4599848A3 (en) Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
MY194313A (en) Substituted chromanes and method of use
WO2015151079A3 (en) Auristatin analogues and their conjugates with cell-binding molecules
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
PH12020500091A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
PH12018502422A1 (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
MX2021002042A (es) Inhibidores de arginasa y sus metodos de uso.
MX2023001445A (es) Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.
NZ759173A (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
MX2020007062A (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.